Lung Stereotactic Radiotherapy for Oligometastases: Comparison of Oligo-recurrence and Sync-oligometastases

Overview

Journal Jpn J Clin Oncol

Publisher Oxford University Press

Specialty Oncology

Date 2016 May 11

PMID 27162324

Citations 23

Authors

Hideomi Yamashita

Yuzuru Niibe

Takaya Yamamoto

Kuniaki Katsui

Keiichi Jingu

Susumu Kanazawa

Atsuro Terahara

Keiichi Nakagawa

Affiliations

Soon will be listed here.

Abstract

Background: Oligometastases can be divided into sync-oligometastases and oligo-recurrence. The difference is whether the primary site is uncontrolled or controlled. The goal of this multicenter study was to evaluate treatment outcomes and factors affecting survival after stereotactic body radiotherapy for pulmonary oligometastases.

Methods: The information after stereotactic body radiotherapy from January 2004 to April 2014 was retrospectively collected. Ninety-six patients (65 males, 31 females) were enrolled. Ten cases (10%) were sync-oligometastases, 79 cases (82%) were oligo-recurrences and 7 (7%) were unclassified oligometastases with <6 months of disease-free interval. The median disease-free interval between initial therapy and stereotactic body radiotherapy was 24 months. The median calculated biological effective dose was 105.6 Gy.

Results: The median follow-up period was 32 months for survivors. The 3-year overall survival and relapse-free survival rates were 53% and 32%, respectively. No Grade 5 toxicity occurred. The median overall survival was 23.9 months for sync-oligometastases and 66.6 months for oligo-recurrence (P = 0.0029). On multivariate analysis, sync-oligometastases and multiple oligometastatic tumors were significant unfavorable factors for both overall survival and relapse-free survival.

Conclusions: In stereotactic body radiotherapy for oligometastatic lung tumors, the state of oligo-recurrence has the potential of a significant prognostic factor for survival.

Citing Articles

Oligo-Recurrence in Lung Cancer; The Most Curable State Among Advanced Disease?.

Shimada Y Cancers (Basel). 2024; 16(23).

PMID: 39682272 PMC: 11639969. DOI: 10.3390/cancers16234086.

Treatment of metastatic breast cancer by stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS).

Li X, Sun Y, Tang L, Li Y, Yang X Discov Oncol. 2024; 15(1):733.

PMID: 39616564 PMC: 11609137. DOI: 10.1007/s12672-024-01595-9.

Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence.

Werner R, Steinmann N, Decaluwe H, Date H, De Ruysscher D, Opitz I Eur Respir Rev. 2024; 33(172).

PMID: 38811031 PMC: 11134198. DOI: 10.1183/16000617.0200-2023.

Oligometastases of Esophageal Squamous Cell Carcinoma: A Review.

Sato Y, Tanaka Y, Yokoi R, Tsuchiya H, Sengoku Y, Fukada M Cancers (Basel). 2024; 16(4).

PMID: 38398095 PMC: 10886923. DOI: 10.3390/cancers16040704.

Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression.

Ho C, Tsai J, Chen C, Shiah H, Chen H, Ting L Diagnostics (Basel). 2023; 13(9).

PMID: 37174988 PMC: 10177978. DOI: 10.3390/diagnostics13091597.

References

Niibe Y, Chang J . Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulm Med. 2012; 2012:261096. PMC: 3432385. DOI: 10.1155/2012/261096. View

Weichselbaum R, Hellman S . Oligometastases revisited. Nat Rev Clin Oncol. 2011; 8(6):378-82. DOI: 10.1038/nrclinonc.2011.44. View

Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T . Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011; 101(2):255-9. DOI: 10.1016/j.radonc.2011.05.033. View

Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y . Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2011; 17(1):1-29. DOI: 10.1007/s10147-011-0315-2. View

Takahashi W, Yamashita H, Niibe Y, Shiraishi K, Hayakawa K, Nakagawa K . Stereotactic body radiotherapy for metastatic lung cancer as oligo-recurrence: an analysis of 42 cases. Pulm Med. 2012; 2012:454107. PMC: 3472526. DOI: 10.1155/2012/454107. View

Rusthoven K, Kavanagh B, Burri S, Chen C, Cardenes H, Chidel M . Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009; 27(10):1579-84. DOI: 10.1200/JCO.2008.19.6386. View

Onishi H, Ozaki M, Kuriyama K, Komiyama T, Marino K, Araya M . Stereotactic body radiotherapy for metachronous multisite oligo-recurrence: a long-surviving case with sequential oligo-recurrence in four different organs treated using locally radical radiotherapy and a review of the literature. Pulm Med. 2012; 2012:713073. PMC: 3486341. DOI: 10.1155/2012/713073. View

Norihisa Y, Nagata Y, Takayama K, Matsuo Y, Sakamoto T, Sakamoto M . Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008; 72(2):398-403. DOI: 10.1016/j.ijrobp.2008.01.002. View

Inoue T, Katoh N, Onimaru R, Shirato H . Clinical outcomes of stereotactic body radiotherapy for patients with lung tumors in the state of oligo-recurrence. Pulm Med. 2012; 2012:369820. PMC: 3399335. DOI: 10.1155/2012/369820. View

10.

Niibe Y, Hayakawa K . Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010; 40(2):107-11. PMC: 2813545. DOI: 10.1093/jjco/hyp167. View

11.

Oh D, Ahn Y, Seo J, Shin E, Park H, Lim D . Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol. 2012; 51(5):596-602. DOI: 10.3109/0284186X.2012.681698. View

12.

Jabbour S, Daroui P, Moore D, Licitra E, Gabel M, Aisner J . A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis. 2012; 3(1):4-9. PMC: 3256496. DOI: 10.3978/j.issn.2072-1439.2010.12.09. View

13.

Ricardi U, Filippi A, Guarneri A, Ragona R, Mantovani C, Giglioli F . Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2011; 75(1):77-81. DOI: 10.1016/j.lungcan.2011.04.021. View

14.

Okunieff P, Petersen A, Philip A, Milano M, Katz A, Boros L . Stereotactic Body Radiation Therapy (SBRT) for lung metastases. Acta Oncol. 2006; 45(7):808-17. DOI: 10.1080/02841860600908954. View

15.

Hellman S, Weichselbaum R . Oligometastases. J Clin Oncol. 1995; 13(1):8-10. DOI: 10.1200/JCO.1995.13.1.8. View